NCT07624214phase 1not yet recruiting

Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors

Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

ClinicalTrials.gov

198

Enrollment · estimated

Countries · 1 sites

2028-04

Primary completion

3 mo ago

Record updated

Commercial relevance

Trial record references molecular eligibility required.

Molecular eligibility required

Biomarker requirement language

Participants with histologically or cytologically confirmed advanced solid tumors harboring a KRAS G12D mutation;
leptomeningeal metastases, brainstem metastases, or spinal cord compression confirmed by imaging (regardless of symptoms) Other inclusion/exclusion criteria may apply.

Change timeline

No changes detected yet. The first refresh records a baseline snapshot; subsequent refreshes generate field-level changes.

Signals from this trial

New trial
53/100
Opportunity
New phase 1 trial NCT07624214 posted by Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.: "Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors".
ClinicalTrials.gov record updated 97 days ago.

Eligibility — raw, for validation

Inclusion Criteria:

* Participants with histologically or cytologically confirmed advanced solid tumors harboring a KRAS G12D mutation;
* Failed standard therapy, intolerant to standard therapy, or no standard therapy is available;
* ECOG Performance Status of 0 or 1;
* Adequate organ function

Exclusion Criteria:

* History of ≥2 primary malignancies within 5 years prior to signing informed consent, except for adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, or other malignancies considered cured;
* Primary central nervous system (CNS) tumors
* leptomeningeal metastases, brainstem metastases, or spinal cord compression confirmed by imaging (regardless of symptoms) Other inclusion/exclusion criteria may apply.